LUM-201
Pediatric Growth Hormone Deficiency (PGHD)
Phase 2bActive
Key Facts
About Lumos Pharma
Lumos Pharma is a clinical-stage biotech dedicated to developing oral therapies for rare diseases, with a lead program targeting Pediatric Growth Hormone Deficiency (PGHD). Its strategy centers on identifying compounds for clear, high-need pathophysiology to enable time- and cost-efficient development. A key achievement was the successful merger with NewLink Genetics, which provided a public listing and resources, and recent Phase 2 trials for LUM-201 have met primary and secondary endpoints, positioning the company for a pivotal Phase 3 study.
View full company profile